Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Analysis of Short-term (Operating) Activity Ratios

Beginner level

Short-term Activity Ratios (Summary)

Regeneron Pharmaceuticals Inc., short-term (operating) activity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Turnover Ratios
Inventory turnover 0.26 0.16 0.28 0.49 1.01
Receivables turnover 2.30 2.38 2.42 2.49 2.33
Payables turnover 0.87 0.82 1.14 1.44 1.71
Working capital turnover 0.86 0.82 1.16 1.72 1.28
Average No. Days
Average inventory processing period 1,426 2,334 1,309 749 360
Add: Average receivable collection period 159 153 151 147 156
Operating cycle 1,585 2,487 1,460 896 516
Less: Average payables payment period 421 442 321 253 213
Cash conversion cycle 1,164 2,045 1,139 643 303

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Regeneron Pharmaceuticals Inc.’s inventory turnover ratio deteriorated from 2017 to 2018 but then improved from 2018 to 2019 not reaching 2017 level.
Receivables turnover An activity ratio equal to revenue divided by receivables. Regeneron Pharmaceuticals Inc.’s receivables turnover ratio deteriorated from 2017 to 2018 and from 2018 to 2019.
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Regeneron Pharmaceuticals Inc.’s payables turnover ratio decreased from 2017 to 2018 but then slightly increased from 2018 to 2019.
Working capital turnover An activity ratio calculated as revenue divided by working capital. Regeneron Pharmaceuticals Inc.’s working capital turnover ratio deteriorated from 2017 to 2018 but then slightly improved from 2018 to 2019.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Regeneron Pharmaceuticals Inc.’s number of days of inventory outstanding deteriorated from 2017 to 2018 but then improved from 2018 to 2019 not reaching 2017 level.
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Regeneron Pharmaceuticals Inc.’s number of days of receivables outstanding deteriorated from 2017 to 2018 and from 2018 to 2019.
Operating cycle Equal to average inventory processing period plus average receivables collection period. Regeneron Pharmaceuticals Inc.’s operating cycle deteriorated from 2017 to 2018 but then improved from 2018 to 2019 not reaching 2017 level.
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Regeneron Pharmaceuticals Inc.’s number of days of payables outstanding increased from 2017 to 2018 but then slightly decreased from 2018 to 2019.
Cash conversion cycle A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. Regeneron Pharmaceuticals Inc.’s cash conversion cycle deteriorated from 2017 to 2018 but then improved from 2018 to 2019 not reaching 2017 level.

Inventory Turnover

Regeneron Pharmaceuticals Inc., inventory turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Cost of goods sold 362,300  180,000  202,507  194,624  241,702 
Inventories 1,415,500  1,151,200  726,138  399,356  238,578 
Short-term Activity Ratio
Inventory turnover1 0.26 0.16 0.28 0.49 1.01
Benchmarks
Inventory Turnover, Competitors2
Abbott Laboratories 3.07 3.35 3.43 3.71 3.37
AbbVie Inc. 4.10 4.81 4.39 4.04 2.62
Amgen Inc. 1.22 1.39 1.44 1.52 1.74
Biogen Inc. 2.43 1.95 1.81 1.48 1.39
Bristol-Myers Squibb Co. 1.88 5.48 5.20 3.99 3.20
Eli Lilly & Co. 1.48 1.56 1.36 1.59 1.46
Gilead Sciences Inc. 5.07 5.96 5.46 2.68 2.05
Illumina Inc. 3.00 2.68 2.78 2.44 2.48
Johnson & Johnson 3.05 3.15 2.89 2.66 2.67
Merck & Co. Inc. 2.36 2.48 2.51 2.85 3.18
Pfizer Inc. 1.23 1.50 1.48 1.82 1.28
Vertex Pharmaceuticals Inc. 3.27 3.29 2.46 2.71 2.18
Zoetis Inc. 1.41 1.37 1.24 1.11 1.18
Inventory Turnover, Sector
Pharmaceuticals & Biotechnology 2.20 2.49 2.39 2.39 2.20
Inventory Turnover, Industry
Health Care 5.37 5.78 5.48 5.53 4.86

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Inventory turnover = Cost of goods sold ÷ Inventories
= 362,300 ÷ 1,415,500 = 0.26

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Regeneron Pharmaceuticals Inc.’s inventory turnover ratio deteriorated from 2017 to 2018 but then improved from 2018 to 2019 not reaching 2017 level.

Receivables Turnover

Regeneron Pharmaceuticals Inc., receivables turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Net product sales 4,834,400  4,106,200  3,718,463  3,338,390  2,689,478 
Accounts receivable, trade, net 2,100,000  1,723,700  1,538,642  1,343,368  1,152,489 
Short-term Activity Ratio
Receivables turnover1 2.30 2.38 2.42 2.49 2.33
Benchmarks
Receivables Turnover, Competitors2
Abbott Laboratories 5.88 5.90 5.22 6.42 5.97
AbbVie Inc. 6.13 6.08 5.55 5.39 4.83
Amgen Inc. 5.47 6.29 6.73 6.92 6.99
Biogen Inc. 6.05 5.56 5.79 6.81 7.49
Bristol-Myers Squibb Co. 3.89 4.66 4.43 4.69 4.76
Eli Lilly & Co. 4.91 4.68 5.03 5.27 5.68
Gilead Sciences Inc. 6.18 6.52 6.66 6.64 5.49
Illumina Inc. 6.18 6.48 6.70 6.29 5.76
Johnson & Johnson 5.67 5.79 5.67 6.14 6.53
Merck & Co. Inc. 6.91 5.98 5.84 5.67 6.09
Pfizer Inc. 5.93 6.68 6.39 6.42 5.97
Vertex Pharmaceuticals Inc. 6.57 7.44 8.85 8.47 5.81
Zoetis Inc. 5.76 5.62 5.32 5.35 5.09
Receivables Turnover, Sector
Pharmaceuticals & Biotechnology 5.59 5.76 5.66 5.92 5.85
Receivables Turnover, Industry
Health Care 7.36 7.44 7.29 7.57 7.29

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Receivables turnover = Net product sales ÷ Accounts receivable, trade, net
= 4,834,400 ÷ 2,100,000 = 2.30

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Receivables turnover An activity ratio equal to revenue divided by receivables. Regeneron Pharmaceuticals Inc.’s receivables turnover ratio deteriorated from 2017 to 2018 and from 2018 to 2019.

Payables Turnover

Regeneron Pharmaceuticals Inc., payables turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Cost of goods sold 362,300  180,000  202,507  194,624  241,702 
Accounts payable 418,100  218,200  178,183  134,984  140,962 
Short-term Activity Ratio
Payables turnover1 0.87 0.82 1.14 1.44 1.71
Benchmarks
Payables Turnover, Competitors2
Abbott Laboratories 4.07 4.27 5.14 7.66 8.09
AbbVie Inc. 5.12 4.99 4.78 4.15 2.82
Amgen Inc. 3.18 3.40 3.01 4.54 4.38
Biogen Inc. 3.68 4.90 4.12 5.28 4.64
Bristol-Myers Squibb Co. 3.30 3.46 2.70 2.97 2.50
Eli Lilly & Co. 3.36 4.55 4.30 4.19 3.76
Gilead Sciences Inc. 6.56 6.14 5.37 3.53 3.40
Illumina Inc. 7.22 5.61 5.79 5.31 4.82
Johnson & Johnson 3.23 3.59 3.47 3.13 3.23
Merck & Co. Inc. 3.78 4.07 4.12 4.95 5.90
Pfizer Inc. 2.42 2.41 2.41 2.72 2.67
Vertex Pharmaceuticals Inc. 6.25 3.69 3.72 3.42 1.66
Zoetis Inc. 6.62 6.11 6.80 6.29 5.93
Payables Turnover, Sector
Pharmaceuticals & Biotechnology 3.50 3.75 3.64 3.76 3.75
Payables Turnover, Industry
Health Care 5.76 5.98 5.79 5.95 5.72

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Payables turnover = Cost of goods sold ÷ Accounts payable
= 362,300 ÷ 418,100 = 0.87

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Regeneron Pharmaceuticals Inc.’s payables turnover ratio decreased from 2017 to 2018 but then slightly increased from 2018 to 2019.

Working Capital Turnover

Regeneron Pharmaceuticals Inc., working capital turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Current assets 7,689,100  6,447,600  4,335,030  3,180,188  2,915,095 
Less: Current liabilities 2,096,600  1,442,800  1,135,483  1,241,495  811,162 
Working capital 5,592,500  5,004,800  3,199,547  1,938,693  2,103,933 
 
Net product sales 4,834,400  4,106,200  3,718,463  3,338,390  2,689,478 
Short-term Activity Ratio
Working capital turnover1 0.86 0.82 1.16 1.72 1.28
Benchmarks
Working Capital Turnover, Competitors2
Abbott Laboratories 6.64 5.44 2.44 1.04 4.11
AbbVie Inc. 0.98 6.16 4.00 4.22
Amgen Inc. 3.96 0.93 0.54 0.63 0.70
Biogen Inc. 3.23 2.51 2.30 1.85 2.23
Bristol-Myers Squibb Co. 2.28 3.32 3.64 3.64 5.86
Eli Lilly & Co. 11.54 2.84 4.90 5.16 4.59
Gilead Sciences Inc. 1.08 0.86 1.27 2.67 2.16
Illumina Inc. 0.94 1.24 1.23 1.49 1.49
Johnson & Johnson 8.81 5.51 6.09 1.86 2.16
Merck & Co. Inc. 8.90 11.53 6.52 2.97 3.74
Pfizer Inc. 2.97 4.90 6.74 3.39
Vertex Pharmaceuticals Inc. 1.19 1.12 1.35 1.64 1.15
Zoetis Inc. 2.13 1.83 1.70 2.15 2.33
Working Capital Turnover, Sector
Pharmaceuticals & Biotechnology 3.43 2.88 2.59 2.11 2.38
Working Capital Turnover, Industry
Health Care 5.23 5.12 4.23 3.66 3.63

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Working capital turnover = Net product sales ÷ Working capital
= 4,834,400 ÷ 5,592,500 = 0.86

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Working capital turnover An activity ratio calculated as revenue divided by working capital. Regeneron Pharmaceuticals Inc.’s working capital turnover ratio deteriorated from 2017 to 2018 but then slightly improved from 2018 to 2019.

Average Inventory Processing Period

Regeneron Pharmaceuticals Inc., average inventory processing period calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data
Inventory turnover 0.26 0.16 0.28 0.49 1.01
Short-term Activity Ratio (no. days)
Average inventory processing period1 1,426 2,334 1,309 749 360
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
Abbott Laboratories 119 109 107 98 108
AbbVie Inc. 89 76 83 90 139
Amgen Inc. 300 262 254 241 210
Biogen Inc. 150 187 202 247 263
Bristol-Myers Squibb Co. 194 67 70 92 114
Eli Lilly & Co. 247 233 268 230 250
Gilead Sciences Inc. 72 61 67 136 178
Illumina Inc. 122 136 131 150 147
Johnson & Johnson 119 116 126 137 136
Merck & Co. Inc. 155 147 146 128 115
Pfizer Inc. 296 244 246 201 284
Vertex Pharmaceuticals Inc. 112 111 148 135 168
Zoetis Inc. 258 266 293 329 308
Average Inventory Processing Period, Sector
Pharmaceuticals & Biotechnology 166 147 153 153 166
Average Inventory Processing Period, Industry
Health Care 68 63 67 66 75

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 0.26 = 1,426

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Regeneron Pharmaceuticals Inc.’s number of days of inventory outstanding deteriorated from 2017 to 2018 but then improved from 2018 to 2019 not reaching 2017 level.

Average Receivable Collection Period

Regeneron Pharmaceuticals Inc., average receivable collection period calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data
Receivables turnover 2.30 2.38 2.42 2.49 2.33
Short-term Activity Ratio (no. days)
Average receivable collection period1 159 153 151 147 156
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
Abbott Laboratories 62 62 70 57 61
AbbVie Inc. 60 60 66 68 76
Amgen Inc. 67 58 54 53 52
Biogen Inc. 60 66 63 54 49
Bristol-Myers Squibb Co. 94 78 82 78 77
Eli Lilly & Co. 74 78 73 69 64
Gilead Sciences Inc. 59 56 55 55 66
Illumina Inc. 59 56 55 58 63
Johnson & Johnson 64 63 64 59 56
Merck & Co. Inc. 53 61 63 64 60
Pfizer Inc. 62 55 57 57 61
Vertex Pharmaceuticals Inc. 56 49 41 43 63
Zoetis Inc. 63 65 69 68 72
Average Receivable Collection Period, Sector
Pharmaceuticals & Biotechnology 65 63 65 62 62
Average Receivable Collection Period, Industry
Health Care 50 49 50 48 50

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 2.30 = 159

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Regeneron Pharmaceuticals Inc.’s number of days of receivables outstanding deteriorated from 2017 to 2018 and from 2018 to 2019.

Operating Cycle

Regeneron Pharmaceuticals Inc., operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data
Average inventory processing period 1,426 2,334 1,309 749 360
Average receivable collection period 159 153 151 147 156
Short-term Activity Ratio
Operating cycle1 1,585 2,487 1,460 896 516
Benchmarks
Operating Cycle, Competitors2
Abbott Laboratories 181 171 177 155 169
AbbVie Inc. 149 136 149 158 215
Amgen Inc. 367 320 308 294 262
Biogen Inc. 210 253 265 301 312
Bristol-Myers Squibb Co. 288 145 152 170 191
Eli Lilly & Co. 321 311 341 299 314
Gilead Sciences Inc. 131 117 122 191 244
Illumina Inc. 181 192 186 208 210
Johnson & Johnson 183 179 190 196 192
Merck & Co. Inc. 208 208 209 192 175
Pfizer Inc. 358 299 303 258 345
Vertex Pharmaceuticals Inc. 168 160 189 178 231
Zoetis Inc. 321 331 362 397 380
Operating Cycle, Sector
Pharmaceuticals & Biotechnology 231 210 218 215 228
Operating Cycle, Industry
Health Care 118 112 117 114 125

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 1,426 + 159 = 1,585

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Operating cycle Equal to average inventory processing period plus average receivables collection period. Regeneron Pharmaceuticals Inc.’s operating cycle deteriorated from 2017 to 2018 but then improved from 2018 to 2019 not reaching 2017 level.

Average Payables Payment Period

Regeneron Pharmaceuticals Inc., average payables payment period calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data
Payables turnover 0.87 0.82 1.14 1.44 1.71
Short-term Activity Ratio (no. days)
Average payables payment period1 421 442 321 253 213
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Abbott Laboratories 90 85 71 48 45
AbbVie Inc. 71 73 76 88 130
Amgen Inc. 115 107 121 80 83
Biogen Inc. 99 74 89 69 79
Bristol-Myers Squibb Co. 110 105 135 123 146
Eli Lilly & Co. 109 80 85 87 97
Gilead Sciences Inc. 56 59 68 103 107
Illumina Inc. 51 65 63 69 76
Johnson & Johnson 113 102 105 116 113
Merck & Co. Inc. 97 90 89 74 62
Pfizer Inc. 151 152 151 134 137
Vertex Pharmaceuticals Inc. 58 99 98 107 220
Zoetis Inc. 55 60 54 58 62
Average Payables Payment Period, Sector
Pharmaceuticals & Biotechnology 104 97 100 97 97
Average Payables Payment Period, Industry
Health Care 63 61 63 61 64

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 0.87 = 421

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Regeneron Pharmaceuticals Inc.’s number of days of payables outstanding increased from 2017 to 2018 but then slightly decreased from 2018 to 2019.

Cash Conversion Cycle

Regeneron Pharmaceuticals Inc., cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data
Average inventory processing period 1,426 2,334 1,309 749 360
Average receivable collection period 159 153 151 147 156
Average payables payment period 421 442 321 253 213
Short-term Activity Ratio
Cash conversion cycle1 1,164 2,045 1,139 643 303
Benchmarks
Cash Conversion Cycle, Competitors2
Abbott Laboratories 91 86 106 107 124
AbbVie Inc. 78 63 73 70 85
Amgen Inc. 252 213 187 214 179
Biogen Inc. 111 179 176 232 233
Bristol-Myers Squibb Co. 178 40 17 47 45
Eli Lilly & Co. 212 231 256 212 217
Gilead Sciences Inc. 75 58 54 88 137
Illumina Inc. 130 127 123 139 134
Johnson & Johnson 70 77 85 80 79
Merck & Co. Inc. 111 118 120 118 113
Pfizer Inc. 207 147 152 124 208
Vertex Pharmaceuticals Inc. 110 61 91 71 11
Zoetis Inc. 266 271 308 339 318
Cash Conversion Cycle, Sector
Pharmaceuticals & Biotechnology 127 113 118 118 131
Cash Conversion Cycle, Industry
Health Care 55 51 54 53 61

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 1,426 + 159421 = 1,164

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Cash conversion cycle A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. Regeneron Pharmaceuticals Inc.’s cash conversion cycle deteriorated from 2017 to 2018 but then improved from 2018 to 2019 not reaching 2017 level.